You are here

Report Cards for Hospital-Acquired Bedsores: How Good Are the Grades?

Study questions Medicare data (October 14)

The data Medicare uses to publicly report hospital rates of patients developing pressure ulcers (bedsores) is not an accurate source for comparing hospitals on how well they prevent the condition, according to a new study from the University of Michigan.

Bedsores are among many common hospital-acquired conditions that Medicare’s Hospital Compare website reports in an effort to help consumers compare the quality of their care at different hospitals.

Hospital bedsore rates varied widely based on how the data were collected, unfairly making some hospitals appear to fare better or worse than others, according to the new findings, which appear in the Annals of Internal Medicine.

Overall, bedsore rates were about 10 times lower when they were based on billing data compared with rates calculated from bedside exams by nurses. In bedside exams, trained teams of independent nurses record rates by periodically evaluating patients for bedsores through a comprehensive skin exam. In contrast, hospital-acquired pressure ulcer cases are identified by hospital coders generating billing data based on how physicians and wound care teams describe wounds in their medical record notes.

“Our findings provide a strong case for removing hospital rates for pressure ulcers from the Medicare’s Hospital Compare website in order to prevent comparisons that may be misleading to patients and policymakers,” said lead author Jennifer Meddings, MD, MSc.

Source: University of Michigan; October 14, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress